Latest News

Understanding who is using the latest nicotine product – oral nicotine pouches – is the key to developing future research on the pouches' effects.

Anthony Cannella has always been willing to try the newest treatments for lymphoma. So he readily agreed to sign up for a CAR-T clinical trial at Hollings.

The Engevik sisters live for science – and they get to do it together at MUSC.

Dr. Jennifer Dahne's focus on making behavioral health interventions accessible to more people has been recognized with a governor's award.

Hollings enrolled the first patient in a clinical trial of a new type of drug, a bifunctional antibody, for head and neck squamous cell carcinoma.

15 years after a terminal diagnosis, Nathan Calhoun is alive thanks to a clinical trial. It's why he performed at LOWVELO in 2024.

Gene therapy is being used against diseases like sickle cell and hemophilia. Could it be used against cancer?

Hollings researchers want to help older adults with head and neck cancer navigate treatment options that have mostly been studied among middle-aged adults.

MUSC Hollings Cancer Center researchers will test whether e-cigarettes are a viable quit smoking option for people who decline other options.

The U.S. surgeon general is calling attention to the link between alcohol and cancer, a connection that may be news to the general public.